NCT02744898View on ClinicalTrials.gov

A Phase 2 Feasibility Study of Abraxane and Carboplatin in Epithelial Neoplasms of the Uterus

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

August 17, 2018

Study Completion Date

March 1, 2020

Conditions
Endometrial Cancer
Interventions
DRUG

Carboplatin AUC

DRUG

Abraxane

100mg/m2

Trial Locations (1)

10016

NYU Perlmutter Cancer Center, New York

All Listed Sponsors
lead

NYU Langone Health

OTHER

NCT02744898 - A Phase 2 Feasibility Study of Abraxane and Carboplatin in Epithelial Neoplasms of the Uterus | Biotech Hunter | Biotech Hunter